ghk-cu clinical trial skin anti-aging randomized Epigenetic mechanisms activated by increase collagen density in GHK-Cu: Mechanism of Action, Collagen
Description
Clinical trial data from the SURMOUNT-1 study showed that gastrointestinal adverse events were significantly more common during dose escalation periods (Jastreboff et al., 2022, NEJM)
Farsky S
MS treatment transformation Approval of the first DMTs The pivotal clinical trial of Biogens intramuscular interferon beta-1a (IFN -1a
Omega-3 fatty acids: 1,000-2,000mg EPA/DHA daily
